Search Results 1281-1290 of 21951 for Inhibition

1. A Study to Evaluate Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients with Chronic Myeloid Leukemia and Persistently- Detectable Minimal Residual Disease - Mayo Clinic

   Patients should not be receiving concomitant strong CYP3A4 inducers or inhibitors ≤ 7 days prior to registration due to their potential to effect the ...

2. A Study To Evaluate The Long-term Safety And Tolerability Of Inhaled LIQ861(Treprostinil) In Pulmonary Arterial Hypertension Patients - Mayo Clinic

   The patient is taking any excluded medications listed in the Investigator's Brochure, namely inhibitors and inducers of CYP2C8. The patient has a ...

3. A Study To Assess The Anti-fatigability Effect Of CK-2127107 In Elderly Male And Female Subjects With Limitations In Mobility - Mayo Clinic

   Participation eligibility · Strong cytochrome P450 (CYP) 3A4 inhibitor (e.g., itraconazole, clarithromycin; within 14 days prior to day 1 · CYP3A4 inducer (e.g., ...

4. Benign prostatic hyperplasia (BPH) - Diagnosis and treatment - Mayo Clinic

   5-alpha reductase inhibitors. ... Your health care provider might suggest that you take an alpha blocker and a 5-alpha reductase inhibitor at the same time if ...

5. Publications - Lionel Kankeu Fonkoua, M.D. - Mayo Clinic

   AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells. Cancer Immunol Res. 2023 Sep 01; 11(9):1222-1236. View PubMed; Yoon HH ...

6. Combination Therapy of Acalabrutinib, Venetoclax and Durvalumab to Treat Richter Transformation - Mayo Clinic

   ... inhibition of ovulation is not the primary mode of action [excluding ... Patients taking proton pump inhibitor will be excluded. NOTE: Patient may be ...

7. Astrocytoma - Symptoms and causes - Mayo Clinic

   DH inhibition in gliomas: From preclinical models to clinical trials. Nature Review Neurology. 2024; doi:10.1038/s41582-024-00967-7. Recht LD, et al ...

8. Publications - Jeremy C. Jones, M.D. - Mayo Clinic

   Multikinase inhibitors in refractory metastatic colorectal cancer: an optimal sequence? ... inhibitor in the first-line setting. Eur J Cancer. 2024 Jan ...

9. A Study Comparing CAR-T Therapy Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants with Relapsed and Lenalidomide-Refractory Multiple Myeloma - Mayo Clinic

   Have received 1 to 3 prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD). Have documented evidence of PD by ...

10. A Study to Evaluate the Effectiveness and Safety of Camidanlumab Tesirine (ADCT-301) in Patients with Relapsed or Refractory Hodgkin Lymphoma - Mayo Clinic

    ... inhibitor approved for cHL (e.g., nivolumab or pembrolizumab). Note: Receipt of HSCT to be included in the number of prior therapies needed to meet ...